OR-RADISYS-CORPORATION
9.3.2022 14:02:06 CET | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced that Korean small cells player Qucell Networks is leveraging Radisys' Connect RAN gNodeB software to enable and deploy 5G small cell solutions for global markets. The integrated commercial-grade 5G small cell solution is being trialed in multiple operators’ networks across the globe.
Radisys’ 3GPP-compliant Connect RAN 5G software enables an elastic and agile 5G network tailored to meet the unique requirements of diverse 5G applications with minimized CAPEX, improved time-to-market, and shortened time-to-revenue. Qucell Networks’ 5G small cells meet varied requirements and enable multiple deployment scenarios in mmWave, Sub-6 GHz, Non-Standalone (NSA), Standalone (SA) and support advanced use cases in residential, enterprise, and outdoor scenarios.
News Highlights
- Radisys’ Connect RAN gNodeB software enables Qucell Networks’ 5G small cells to support high capacity, robust connectivity, low latency and secure 5G networks for advanced uses cases such as smart factories, healthcare, education, stadiums, enterprises, retail and other private 5G use cases.
- The ruggedized and feature-rich 5G small cell solution from Radisys and Qucell offers operators a commercial-grade, deployment-ready solution.
- Radisys’ Connect RAN 5G is the first-to-market protocol software compliant with 3GPP Release 16 and delivers enhancements in functionality, capacity, coverage, latency, mobility, reliability, and ease of deployment. It also supports the FAPI and nFAPI specifications from the Small Cell Forum (SCF), and it is compliant with O-RAN Alliance architecture. Connect RAN 5G software won the SCF Small Cell Award for Outstanding Contribution to Small Cell Open RAN Platforms.
- The software is available integrated on multiple industry-leading platforms to accelerate global 5G deployments.
“We are seeing growing demand for 5G small cells as global operators roll out their 5G networks and enterprises seek to deploy 5G private networks,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “We’ve teamed with Qucell to meet this demand with a pre-integrated, feature-rich solution for our customers.”
“We are excited to partner with Radisys on 5G small cells that deliver robust connectivity and high performance for a variety of indoor and outdoor use cases,” said Young-Soo Kwak, CEO, Qucell Networks. “Radisys is the leader in 5G software, and this integrated solution offers our joint customers an easy path to 5G deployment.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
About Qucell Networks
Qucell Networks is a 5G and LTE small cells vendor and solutions provider. World-class mobile network operators have been deploying Qucell LTE solutions since 2012. What differentiates Qucell from competitors is a proven and commercially ready comprehensive suite of LTE and 5G small cells solutions. Qucell offers timely, effective turnkey products to solve real problems in commercial environments. Qucell partnerships with pioneers in small cells technology have resulted in proven cutting-edge products and professional services. For more information, visit QUCELL .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005157/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom